Home/Pipeline/4'-Thio-2'-Deoxycytidine (TdCyd)

4'-Thio-2'-Deoxycytidine (TdCyd)

Advanced Solid Tumors

Phase 1Active

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase 1

Status

Active

Company

Alchem Laboratories

About Alchem Laboratories

Alchem Laboratories is a long-established, private biotech firm with a dual focus on infectious disease therapeutics and a robust contract development and manufacturing (CDMO) service for clinical-stage APIs. Its core capabilities include custom synthesis, assay development, and high-throughput screening (HTS), supported by leadership with deep experience in drug delivery and government contracting. While its public pipeline data shows activity in oncology and other areas, its stated mission centers on advancing antiviral and antibody treatments, positioning it at the intersection of internal R&D and external service provision.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active